Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke
dc.creator | Schweizer J., Arnold M., König I.R., Bicvic A., Westphal L.P., Schütz V., Inauen C., Scherrer N., Luft A., Galovic M., Ferreira Atuesta C., Pokorny T., Arnold M., Fischer U., Bonati L.H., De Marchis G.M., Kahles T., Nedeltchev K., Cereda C.W., Kägi G., Bustamante A., Montaner J., Ntaios G., Sagris D., Foerch C., Spanaus K., von Eckardstein A., Katan M. | en |
dc.date.accessioned | 2023-01-31T09:54:45Z | |
dc.date.available | 2023-01-31T09:54:45Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1016/j.jacc.2022.01.042 | |
dc.identifier.issn | 07351097 | |
dc.identifier.uri | http://hdl.handle.net/11615/78864 | |
dc.description.abstract | Background: Midregional pro-atrial natriuretic peptide (MR-proANP) is a promising biomarker to differentiate the underlying etiology of acute ischemic stroke (AIS). Objectives: This study aimed to determine the role of MR-proANP for classification as cardioembolic (CE) stroke, identification of newly diagnosed atrial fibrillation (NDAF), and risk assessment for major adverse cardiovascular events (MACE). Methods: This study measured MR-proANP prospectively collected within 24 hours after symptom-onset in patients with AIS from the multicenter BIOSIGNAL (Biomarker Signature of Stroke Aetiology) cohort study. Primary outcomes were CE stroke etiology and NDAF after prolonged cardiac monitoring, as well as a composite outcome of MACE (recurrent cerebrovascular events, myocardial infarction, or cardiovascular death) within 1 year. Logistic/Poisson and subproportional hazard regression were applied to evaluate the association between MR-proANP levels and outcomes. Additionally, a model for prediction of NDAF was derived and validated as a decision tool for immediate clinical application. Results: Between October 1, 2014, and October 31, 2017, this study recruited 1,759 patients. Log10MR-proANP levels were associated with CE stroke (OR: 7.96; 95% CI: 4.82-13.14; risk ratio: 3.12; 95% CI: 2.23-4.37), as well as NDAF (OR: 35.3; 95% CI: 17.58-71.03; risk ratio: 11.47; 95% CI: 6.74-19.53), and MACE (subdistributional HR: 2.02; 95% CI: 1.32-3.08) during follow-up. The model to predict NDAF including only age and MR-proANP levels had a good discriminatory capacity with an area under the curve of 0.81 (95% CI: 0.76-0.86), was well calibrated (calibration in the large: −0.086; calibration slope 1.053), and yielded higher net-benefit compared with validated scores to predict NDAF (AS5F score, CHA2DS2-VASc [Congestive Heart Failure, Hypertension, Age ≥65 or ≥75, Diabetes, Prior Cardioembolic Event, (female) Sex, or Vascular Disease] score). Conclusions: MR-proANP is a valid biomarker to determine risk of NDAF and MACE in patients with AIS and can be used as a decision tool to identify patients for prolonged cardiac monitoring. (Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL study [BIOSIGNAL]; NCT02274727) © 2022 American College of Cardiology Foundation | en |
dc.language.iso | en | en |
dc.source | Journal of the American College of Cardiology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127085063&doi=10.1016%2fj.jacc.2022.01.042&partnerID=40&md5=802a64f57c19e9801834741dd89dea6e | |
dc.subject | atrial natriuretic factor | en |
dc.subject | midregional pro atrial natriuretic peptide | en |
dc.subject | unclassified drug | en |
dc.subject | atrial natriuretic factor | en |
dc.subject | biological marker | en |
dc.subject | acute ischemic stroke | en |
dc.subject | adult | en |
dc.subject | age | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | atrial fibrillation | en |
dc.subject | cardioembolic stroke | en |
dc.subject | cardiovascular mortality | en |
dc.subject | cardiovascular risk | en |
dc.subject | CHA2DS2-VASc score | en |
dc.subject | cohort analysis | en |
dc.subject | congestive heart failure | en |
dc.subject | controlled study | en |
dc.subject | diabetes mellitus | en |
dc.subject | female | en |
dc.subject | heart infarction | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | prospective study | en |
dc.subject | risk assessment | en |
dc.subject | sex factor | en |
dc.subject | atrial fibrillation | en |
dc.subject | brain ischemia | en |
dc.subject | cerebrovascular accident | en |
dc.subject | clinical trial | en |
dc.subject | complication | en |
dc.subject | multicenter study | en |
dc.subject | Atrial Fibrillation | en |
dc.subject | Atrial Natriuretic Factor | en |
dc.subject | Biomarkers | en |
dc.subject | Cohort Studies | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Ischemic Stroke | en |
dc.subject | Prospective Studies | en |
dc.subject | Risk Assessment | en |
dc.subject | Stroke | en |
dc.subject | Elsevier Inc. | en |
dc.title | Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |